Pharma BD Deal Intelligence
A win, not a bust: Merck paid $250M to exercise its option on Moderna's individualized neoantigen therapy for melanoma, and five-year KEYNOTE-942 follow-up confirmed a durable 49% reduction in recurrence or death risk—validating the mRNA-cancer-vaccine bet well ahead of 2027 Phase 3 readouts.
Merck will pay Moderna $250 million to opt into a co-development agreement for mRNA-4157, an experimental personalized cancer vaccine, the companies announced…
Merck has exercised an option to jointly develop and commercialize Moderna's personalized cancer vaccine mRNA-4157, paying $250 million to enter a 50-50 cost…
Moderna and Merck presented 5-year KEYNOTE-942 data for intismeran autogene (mRNA-4157/V940) + Keytruda in high-risk resected stage III/IV melanoma at the…
Source summaries from our enrichment pipeline; follow links for originals.
All 14 sources with sentiment breakdown →
Merck and Moderna expanded their existing cancer vaccine collaboration to jointly develop and commercialize mRNA-4157/V940 — now known by its international nonproprietary name intismeran autogene — an individualized neoantigen therapy (INT), in combination with Keytruda (pembrolizumab) for the adjuvant treatment of high-risk resected melanoma and other tumor types. Merck paid $250M upfront to exercise its option for a worldwide 50/50 cost and profit share. The pivotal evidence base is the Phase 2b KEYNOTE-942 trial: initial data showed a 44% reduction in recurrence or death versus Keytruda monotherapy, and five-year follow-up data reported in January 2026 (and presented at the 2026 ASCO Annual Meeting) demonstrated a sustained 49% reduction in the risk of recurrence or death (HR 0.510; 95% CI 0.294-0.887). The pivotal Phase 3 INTerpath-001 melanoma trial is fully enrolled, and Phase 3 NSCLC studies (INTerpath-002 and INTerpath-009) remain in enrollment, with key confirmatory readouts anticipated in 2027.
236K US cases/yr · $28.0B US NSCLC market (2024) · ~26% 5-year survival rate (all stages)
Non-small cell lung cancer accounts for ~85% of all lung cancers. Despite advances in immunotherapy and targeted therapy, recurrence remains a major challenge in resectable disease. Personalized neoantigen vaccines represent a novel adjuvant approach.
Merck and Moderna initiated INTerpath-009, a Phase 3 trial evaluating V940 + Keytruda as adjuvant therapy in resectable Stage II-IIIB NSCLC patients who did not achieve pCR after neoadjuvant Keytruda + chemotherapy. Additional Phase 2 studies are ongoing in renal cell carcinoma, urothelial carcinoma, and cutaneous squamous cell carcinoma.
100K US cases/yr · $8M 2024 melanoma market
Cutaneous melanoma is a malignancy arising from melanocytes, most often on sun-exposed skin, with approximately 100,000 new US cases and ~8,000 deaths estimated annually. 'High-risk' melanoma generally denotes resected stage IIB-IIIC-IV disease, where the risk of recurrence after surgery ranges from roughly 30% to more than 50% within five years depending on tumor thickness, ulceration, and nodal involvement. Five-year relative survival is approximately 94% overall but falls to roughly 35% for distant-metastatic disease. Standard adjuvant treatment for high-risk resected disease includes anti-PD-1 monotherapy (pembrolizumab, nivolumab) and, for BRAF V600-mutant tumors, dabrafenib plus trametinib; personalized neoantigen vaccines combined with checkpoint inhibition are under investigation to further reduce recurrence.
Personalized neoantigen vaccine therapy (mRNA-4157/V940 + Keytruda) represents a leading mRNA oncology platform. The competitive landscape includes checkpoint inhibitors and adjuvant immunotherapy regimens. Merck and Moderna are primary players with significant first-mover advantage.
97K US cases/yr · $8.5B Global adjuvant and metastatic melanoma therapeutics market 2023 · 44% Recurrence/death reduction vs Keytruda monotherapy (KEYNOTE-942)
Cutaneous melanoma accounts for approximately 97,000 new U.S. cases annually and ~7,600 U.S. deaths, with dramatic survival improvements over the past decade driven by PD-1/CTLA-4 checkpoint inhibitors and BRAF/MEK combinations. The Merck-Moderna collaboration targets the adjuvant high-risk resected stage III/IV setting, where ~5,000-8,000 U.S. patients per year currently receive adjuvant Keytruda (pembrolizumab) or Opdivo (nivolumab) monotherapy under FDA labels from the KEYNOTE-054 and CheckMate-238 trials. Despite checkpoint adjuvant improving recurrence-free survival, roughly 50% of high-risk resected patients still recur within 5 years, creating a large unmet need for recurrence-prevention add-ons. mRNA-4157 (V940, now labeled mRNA-4157) is an individualized neoantigen therapy (INT) tailored per-patient from tumor sequencing — the first INT to produce randomized Phase 2b evidence of benefit when added to Keytruda, with KEYNOTE-942 (published 2023) showing a 44% reduction in recurrence or death versus Keytruda monotherapy. The addressable adjuvant high-risk melanoma population is the commercial beachhead, with Phase 3 INTerpath-001 confirmation underway and potential label expansion into NSCLC adjuvant (INTerpath-009) and muscle-invasive bladder cancer representing the broader Merck-Moderna INT franchise thesis.
The adjuvant melanoma competitive landscape is anchored by PD-1 monotherapy. Keytruda (pembrolizumab, Merck) holds KEYNOTE-054 adjuvant stage III approval with $25B+ 2023 global sales across all indications. Opdivo (nivolumab, Bristol Myers Squibb) is approved adjuvant stage IIB/III/IV from CheckMate-238. Yervoy (ipilimumab, BMS) is a minority-used adjuvant CTLA-4 option for high-risk stage III; the Opdivo-Yervoy combo in metastatic sets the I-O doublet benchmark. BRAF/MEK combos Tafinlar+Mekinist (dabrafenib+trametinib, Novartis) serve BRAF V600-mutant adjuvant (COMBI-AD) and metastatic. The Merck-Moderna mRNA-4157 INT approach competes against neoantigen-targeted platforms from Gritstone bio (GRANITE/SLATE), BioNTech (BNT122/autogene cevumeran, Roche-partnered), and Nouscom (NOUS-209 MSI-high neoantigen). mRNA-4157 is the only INT with randomized Phase 2b efficacy data in adjuvant melanoma, giving Merck-Moderna a multi-year competitive lead in individualized cancer vaccines as the category transitions to Phase 3 confirmatory trials.
Merck exercised option for co-development of mRNA-4157/V940 with Keytruda for melanoma.
Intismeran autogene (mRNA-4157/V940) + Keytruda sustained a 49% reduction in recurrence/death (HR 0.510) at 5 years in resected high-risk melanoma; presented at ASCO 2026. Compound received INN 'intismeran autogene'.
INTerpath-001 melanoma Phase 3 fully enrolled. NSCLC Phase 3 enrolling. Landmark cancer vaccine platform.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Merck & Co. Inc. / Moderna, Inc. (this deal) | 2022 | $250M | 86 |
| Merck & Co. Inc. / Acceleron Pharma Inc. | 2021 | $11.5B | 90 |
| Merck & Co. Inc. / Peloton Therapeutics Inc. | 2019 | $2.2B | 88 |
| Merck & Co. Inc. / AstraZeneca PLC | 2017 | $8.5B | 87 |
| Merck & Co. Inc. / Moderna, Inc. | 2016 | $250M | 84 |
| Merck & Co. Inc. / Eisai Co., Ltd. | 2018 | $5.8B | 83 |
| Merck & Co. Inc. / Prometheus Biosciences Inc. | 2023 | $10.8B | 77 |
← Browse all deals · How we score deals
More: 2022 deals · Merck & Co. Inc. deals · Oncology deals